Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7056733 | 0.98 | KCNH2 (0.34) | KCNH2 | |
| SCHEMBL7060405 | 0.98 | KCNH2 (0.34) | KCNH2 | |
| SCHEMBL7061452 | 0.98 | KCNH2 (0.34) | KCNH2 | |
| SCHEMBL961102 | 0.98 | KCNH2 (0.34) | KCNH2 | |
| SCHEMBL8337997 | 0.98 | KCNH2 (0.34) | KCNH2 | |
| SCHEMBL7058385 | 0.98 | KCNH2 (0.34) | KCNH2 | |
| SCHEMBL2493950 | 0.98 | KCNH2 (0.34) | KCNH2 | |
| SCHEMBL7206068 | 0.98 | KCNH2 (0.34) | KCNH2 | |
| SCHEMBL7056094 | 0.98 | KCNH2 (0.34) | KCNH2 | |
| SCHEMBL7054565 | 0.98 | KCNH2 (0.34) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118140318-A | Negative electrode aqueous slurry composition for lithium ion electric storage device | PPG工业俄亥俄公司 | 2024-06-04 | — | — | CN | claimed |
| CN-115108987-B | N-substituted indenoisoquinolinone derivative and preparation method thereof | 华侨大学 | 2023-05-26 | — | — | CN | claimed |
| EP-3236936-B1 | AMPHIPHILIC POLYMER SYSTEMS | UNIV BASEL (CH) | 2020-02-19 | — | — | EP | claimed |
| EP-3442501-A1 | COMPOSITIONS AND METHODS FOR MAINTAINING OR ENHANCING HOMEOSTASIS OR FUNCTION OF FEMALE LOWER REPRODUCTIVE TRACT | Fairhaven Health, LLC (US) | 2019-02-20 | — | — | EP | claimed |
| EP-2641927-B1 | Thermosensitive copolymers, and forward osmosis water treatment devices and methods of using the same | SAMSUNG ELECTRONICS CO LTD (KR) | 2018-10-17 | — | — | EP | claimed |
| CN-107567330-A | Amphipathic nature polyalcohol system | 巴塞尔大学医院 | 2018-01-09 | — | — | CN | claimed |
| US-20170369655-A1 | AMPHIPHILIC POLYMER SYSTEMS | UNIVERSITÄTSSPITAL BASEL (CH) | 2017-12-28 | — | — | US | claimed |
| EP-3236936-A1 | AMPHIPHILIC POLYMER SYSTEMS | Universitätsspital Basel (CH) | 2017-11-01 | — | — | EP | claimed |
| WO-2017180174-A1 | COMPOSITIONS AND METHODS FOR MAINTAINING OR ENHANCING HOMEOSTASIS OR FUNCTION OF FEMALE LOWER REPRODUCTIVE TRACT | FAIRHAVEN HEALTH, LLC (US) | 2017-10-19 | — | — | WO | claimed |
| CN-105001175-B | A kind of preparation method of 2 aryl 2 oxazoline | 安阳师范学院 | 2017-03-01 | — | — | CN | claimed |
| US-6440942-B1 | MODIFICATIONS TO ENHANCE ACID STABILITY AND PREVENT ANHYDRO FORMATION; ROXITHROMYCIN AND CLARITHROMYCIN; ACTIVE AGAINST MLS-RESISTANT STRAINS (MLS=MACROLIDES-LINCOSAMIDES-STREPTOGRAMINES) | ENANTA PHARMACEUTICALS, INC. | 2002-08-27 | — | — | US | claimed |
| US-6436906-B1 | NOVEL MACROLIDES HAVING ANTIBACTERIAL ACTIVITY TOWARD GRAMPOSITIVE AND GRAMNEGATIVE BACTERIA AS WELL AS MACROLIDE RESISTANT GRAMPOSITIVES | ENANTA PHARMACEUTICALS, INC. | 2002-08-20 | — | — | US | claimed |
| WO-2002060912-A1 | 14-MEMBERED MACROLIDES DERIVED FROM LEUCOMYCINS | ENANTA PHARMACEUTICALS, INC. (US) | 2002-08-08 | — | — | WO | claimed |
| US-20020016355-A1 | Synthesis of clasto-lactacystin beta-lactone and analogs thereof | SOUCY FRANCOIS (US) | 2002-02-07 | — | — | US | claimed |
| EP-1021407-A4 | SYNTHESIS OF CLASTO-LACTACYSTIN BETA-LACTONE AND ANALOGS THEREOF | MILLENNIUM PHARM INC (US) | 2001-07-04 | — | — | EP | claimed |
| EP-1021407-A1 | SYNTHESIS OF CLASTO-LACTACYSTIN BETA-LACTONE AND ANALOGS THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2000-07-26 | — | — | EP | claimed |
| WO-1999009006-A1 | SYNTHESIS OF CLASTO-LACTACYSTIN β-LACTONE AND ANALOGS THEREOF | SOUCY FRANCOIS (US) | 1999-02-25 | — | — | WO | claimed |
| EP-0468470-B1 | Benzimidazoles, medicaments containing them and process for their preparation | THOMAE GMBH DR K (DE) | 1997-04-16 | — | — | EP | claimed |
| WO-1992011243-A1 | 1-MONO OR 1,3-BIS-SUBSTITUTED IMIDAZOLIUM SALTS AND THEIR BENZO ANALOGUES, PROCESS FOR MANUFACTURE AND THEIR USE | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1992-07-09 | — | — | WO | claimed |
| US-4016192-A | Unsaturated acrylic acid-oxazoline reaction products | THE DOW CHEMICAL COMPANY (US) | 1977-04-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016355-A1 | Synthesis of clasto-lactacystin beta-lactone and analogs thereof | PSMB7, PSMB5, LTN1 | ADRA2A 4413/4885ADRA2B 3956/4885ADRA2C 4233/4885 |
| US-20170369655-A1 | AMPHIPHILIC POLYMER SYSTEMS | ANAPC7, ANXA7, PAICS | ADRA2A 1043/4885ADRA2B 1219/4885ADRA2C 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.